HIGHLIGHTS: David Ricks - CEO of Eli Lilly

Introducing a brand-new podcast series: The Friday Wrap-Up! Tables have turned. Marthe Skaar, Chief of Communications and External Relations at NBIM, sits down with Nicolai Tangen, for a debrief on the latest podcast episode, news about the fund and the markets, and life behind t ...  Show more

What does it take to build one of the world's most successful hedge funds, and keep innovating for nearly 30 years? Nicolai Tangen sits down with Sir Paul Marshall, co-founder of Marshall Wace, to unpack the firm's journey from a $50 million startup in 1997 to a firm managing $90 ...  Show more

(0:00) Introducing Eli Lilly CEO Dave Ricks

(1:43) How Eli Lilly discovered the GLP-1 impact on weight loss, counterfeit products from China

(7:08) GLP-1 pricing and capital allocation after a breakout pharma product

(12:56) Why Biotech VC has plummeted, " ...

On this episode, Dan Nathan sits down with Zachariah Reitano, co-founder and CEO of Ro, to discuss the Ro origin story (2:00), weight-loss medications like Ozempic or Wegovy (11:00), Dan’s Ro Body experience (25:00), drug shortages (35:00), oral alternatives (45:00) and how these ...  Show more

Eli Lilly CEO David Ricks on his company’s innovative approaches to treating Alzheimer’s, developing and delivering Covid-19 therapies, and bringing his workforce back into the office. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about o ...  Show more

Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. Deidre Woollard caught up with Motley Fool biotech analyst Karl Thiel to discuss: - Biogen’s next shot at an Alzheimer’s treatment. - Why companies can’t “muscle their way” i ...  Show more